Lantheus Medical to Begin Phase 3 Trial of Injection Agent for CAD
Lantheus Medical Imaging Inc. has received a Special Protocol Assessment (SPA) approval for a Phase 3 clinical trial for the assessment of myocardial perfusion using PET imaging of an injection agent in patients with suspected coronary artery disease.
Lantheus Medical Imaging Inc. has received a Special Protocol Assessment (SPA) approval for a Phase 3 clinical trial for the assessment of myocardial perfusion using PET imaging of an injection agent in patients with suspected coronary artery disease.
The company plans to start the first of two planned trials of flurpiridaz F-18 in the second quarter of 2011. An SPA means the company’s proposed trial protocol is acceptable for approval.
“We believe that flurpiridaz F-18 can improve the diagnosis and evaluation of coronary artery disease, ultimately reducing the need for additional medical tests and procedures,” Lantheus president and CEO Don Kiepert said in a statement.
Data from a preliminary Phase 2 trial showed that PET imaging with flurpiridaz F-18 provided better image quality than technetium-99m sestamibi singe photon emission computer tomography (SPECT), which is the current standard for noninvasive detection of CAD, according to the company. A full data set from the Phase 2 clinical trial will be presented in May at the Nuclear Cardiology and Cardiac CT Conference.
The goal of the Phase 3 trial is to assess the sensitivity and specificity of flurpiridaz F-18 injection PET myocardial perfusion imaging in about 1,350 patients with known or suspected CAD at about 100 clinical sites.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which will be unveiled at the American College of Cardiology (ACC) conference.
